NR3C2 and hydrops fetalis: However, as we record past medication history and most patients may not start treatment or be given a well-established treatment plan until after this admission; this is the reason why the use of HF key therapies such as diuretics (19%) and aldosterone receptor antagonist (6%) is rather low even in NYAH IV patients.